Erratum: Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study [Ann Oncol, 25, (2015) 611-618] DOI: 10.1093/annonc/mdt556;Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study

Annals of Oncology

Volumn 25, Issue 3, 2014, Pages 611-618

  Dieci, M V ^a,b,c   Criscitiello, C ^d   Goubar, A ^a   Viale, G ^d,e   Conte, P ^b,c   Guarneri, V ^b,c   Ficarra, G ^f   Mathieu, M C ^a   Delaloge, S ^a   Curigliano, G ^b,c   Andre, F ^a,g  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF PADOVA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Triple negative; Tumor lymphocytes

Indexed keywords

EOSIN; HEMATOXYLIN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME;

BREAST CANCER; NEOADJUVANT CHEMOTHERAPY; TRIPLE NEGATIVE; TUMOR LYMPHOCYTES;

FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN;

EID: 84896872171     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv241     Document Type: Erratum

References (12)

1. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012; 366: 2438-2441.
2. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
3. André F, Dieci MV, Dubsky P et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res 2013; 19: 28-33.
4. Demaria S, Volm MD, Shapiro RL et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001; 7: 3025-3030.
5. Ladoire S, Mignot G, Dabakuyo S et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011; 224: 389-400.
6. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
7. Cortazar P, Zhang L, Untch M et al. Meta-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). Cancer Res 2012; 72: S1-11.
8. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
9. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
10. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
11. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. http://www.rproject.org/(July 15, 2013, date last accessed).
12. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicinbased chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.